seed
Stage
About
Developing therapeutics to prevent post‑traumatic osteoarthritis (PTOA), focusing on interventions to block the pathological processes that follow joint injury. Listed by Forty51 Ventures as a Basel‑based portfolio company in 2025.
Explore Cartilla Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.